DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Practical applications of recombinant alpha-1-antitrypsin in medicine].

Author(s): Kabzinski J, Kedziora J, Majsterek I

Affiliation(s): The University of Humanities and Economics in Lodz, Poland.

Publication date & source: 2010-12, Pol Merkur Lekarski., 29(174):345-50.

Publication type: Editorial; English Abstract

Alpha-1-antytripsin deficiency, human plasma protein belonging to serine proteinase inhibitor, is the underlying reason for causing such diseases as liver cirrhosis or pulmonary emphysema. It has been proven that alpha-1-antytripsin deficiency can be treated with replacement therapy of this protein. Because of the risks associated with the administration to patients with deficiency of alpha-1-antytrypsyny protein fractionated from human plasma, the methods of gaining recombinant alpha-1-antytripsin are still being developed. Methods for the production of alpha-1-antytripsin synthesized using transgenic animals can achieve high performance while maintaining a fully functional protein structure. Obtained in this way, alpha-1-antitrypsin gives hope for the use of replacement therapy on a large scale.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017